Cardiff Oncology Inc CRDF:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/03/21 EST
10.11quote price arrow down-0.99 (-8.92%)
Volume
1,074,164
52 week range
0.70 - 25.50

...

Loading . . .

KEY STATS

  • Open11.07
  • Day High11.23
  • Day Low10.01
  • Prev Close10.11
  • 52 Week High25.50
  • 52 Week High Date12/01/20
  • 52 Week Low0.70
  • 52 Week Low Date03/19/20
  • Market Cap374.58M
  • Shares Out37.05M
  • 10 Day Average Volume1.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.88
  • 1 Year % Change535.85

RATIOS/PROFITABILITY

  • EPS (TTM)-1.60
  • P/E (TTM)-6.32
  • Fwd P/E (NTM)-16.15
  • EBITDA (MRQ)-16.131M
  • ROE (MRQ)-100.77%
  • Revenue (MRQ)340,000.00
  • Gross Margin (MRQ)27.28%
  • Net Margin (MRQ)-4,996.07%
  • Debt To Equity (MRQ)0.91%

EVENTS

  • Earnings Date05/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Cardiff Oncology Inc News

There is no recent news for this security.

Latest CRDF News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate...
Rodney Markin M.D., Ph.D.
Chairman
Mark Erlander Ph.D.
Chief Executive Officer
Address
11055 Flintkote Ave
San Diego, CA
92121-1220
United States